Results 161 to 170 of about 725,921 (266)

Endoscopic small bowel therapies for type 2 diabetes

open access: yesNutrition in Clinical Practice, Volume 41, Issue 5, Page 1296-1306, October 2026.
Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel   +4 more
wiley   +1 more source

Effect of GLP‐1 receptor agonist on nutrient intake: A narrative review

open access: yesNutrition in Clinical Practice, Volume 41, Issue 5, Page 1308-1317, October 2026.
Abstract Humans have a primitive defense mechanism called metabolic adaptation that slows voluntary weight loss. It works by downregulating hormones that reduce food intake and by lowering the metabolic rate. Second‐generation GLP‐1 receptor agonists, such as semaglutide or tirzepatide, promote weight loss by targeting this hormonal system to control ...
Ken Fujioka
wiley   +1 more source

Impact of Stabilizing Osmolytes on the Conformational Dynamics of Human and Rat Islet Amyloid Polypeptides

open access: yesProteins: Structure, Function, and Bioinformatics, Volume 94, Issue 10, Page 1717-1737, October 2026.
ABSTRACT The aggregation of human islet amyloid polypeptide (hIAPP) into cytotoxic oligomers and amyloid fibrils is a hallmark of type 2 diabetes mellitus (T2DM), leading to pancreatic β‐cell dysfunction. In contrast, rat IAPP (rIAPP) is largely non‐amyloidogenic. Osmolytes such as glucose, glycerol, and sorbitol are known to stabilize globular protein
Kiara A. Kidman   +3 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Incretin effect helps in regulating glucose homeostasis and maintaining glycaemic control within the human body. This effect is achieved by the two naturally occurring incretin hormones: glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1).
Nora H. J. Alharbi
wiley   +1 more source

Sensory and motor physiological functions are impaired in gastric inhibitory polypeptide receptor-deficient mice. [PDF]

open access: yesJ Diabetes Investig, 2014
Okawa T   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy